Geneos Therapeutics, the cancer immunotherapy startup that is a spinoff of Plymouth Meeting-based Inovio, has managed to raise $10.4 million in a private stock sale, writes John George for the Philadelphia Business Journal.

According to Niranjan Y. Sardesai, the company’s co-founder and CEO, the latest stock sale was an extension of the company’s previous Series A financing that finalized its spinout in February last year.

That financing – led by Texas-based life sciences venture capital firm Santé Ventures – netted the company a $4.5 million initial investment with a milestone-driven option. Inovio also participated in the round.

This time, the two were joined by Korea Investment Partners and its BIO Global Fund for the $10.4 million investment.

Sardesai, who last year stepped down from his position as Inovio’s chief operating officer to serve full-time as Geneos’ CEO, said the proceeds from the financing round will be mainly used to expand GT-30, the company’s lead clinical program.

GT-30 targets hepatocellular cancer, which is a common type of liver cancer. The company is aiming to develop personalized immunotherapies tailored to each patient’s tumor mutations.

Read more about Geneos Therapeutics at the Philadelphia Business Journal by clicking here.